In this meta-analysis, researched compared the diagnostic accuracy point-of-care HIV RNA viral load tests with laboratory-based assays to detect antiretroviral therapy treatment failure in patients with HIV infection.
The expanded approval was supported by data from studies in the adult population and by data from an interim analysis of the phase 1/2 MOCHA study.
Sandra Springer, MD, and Laura Marks, MD, PhD, highlight the need for a combined treatment approach for patients with drug-use associated infections.
In this study, researchers assessed the rate of HIV diagnoses in Black individuals in the United States, particularly among those living in communities with increased social vulnerability.
Cabenuva is a 2-drug co-packaged product that combines cabotegravir, an HIV integrase strand transfer inhibitor, and rilpivirine, an HIV non-nucleoside reverse transcriptase inhibitor.
Gilead has “executed seizures at 17 locations in 9 states, seizing thousands of bottles of Gilead-labeled medication with counterfeit supply chain documentation.”
Researchers conducted a study that compared a multicomponent diagnostic strategy with routine care for the diagnosis and treatment of tuberculosis infection.
The application is supported by data from the phase 2b/3 HPTN 083 and HPTN 084 trials, which evaluated the efficacy and safety of Apretude for HIV PrEP.
The clinical holds were based on observations from trials that showed a decrease in total lymphocyte and CD4+ T-cell counts among patients treated with islatravir.
Researchers conducted a study that compared vaginal cytokine and microbiota profiles before and after condomless vaginal intercourse between women who use vaginal lubricants vs those who do not.
